Catheter Ablation for Ventricular Arrhythmias in Hypertrophic Cardiomyopathy.
Apical aneurysm
Epicardial ablation
Hypertrophic cardiomyopathy
Ventricular arrhythmias
Ventricular tachycardia
Journal
Cardiac electrophysiology clinics
ISSN: 1877-9190
Titre abrégé: Card Electrophysiol Clin
Pays: United States
ID NLM: 101549998
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
22
11
2022
Statut:
ppublish
Résumé
Implantable cardioverter-defibrillators are the mainstay of therapy for prevention of sudden cardiac death in high-risk patients with hypertrophic cardiomyopathy (HCM). Catheter ablation is a useful option for patients with recurrent, drug refractory monomorphic ventricular tachycardia (VT), and device therapy. Compared with other nonischemic substrates, there are limited data on the role and outcomes of catheter ablation in HCM. The challenges of VT ablation in HCM patients include deep intramural and epicardial substrates, suboptimal power delivery, and higher recurrence due to progression of disease. Patient selection, using cardiac MRI scar localization, and optimizing ablation techniques can improve outcomes in these patients.
Identifiants
pubmed: 36396186
pii: S1877-9182(22)00072-7
doi: 10.1016/j.ccep.2022.08.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-699Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.